Xanomeline/Trospium Chloride: First Approval.

IF 13 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI:10.1007/s40265-024-02126-0

Yahiya Y Syed

引用次数: 0

Abstract

Xanomeline/trospium chloride (COBENFY™), formerly KarXT, is a first-in-class, oral, fixed-dose muscarinic agonist/antagonist combination being developed for use in schizophrenia and Alzheimer's disease psychosis. Xanomeline is thought to confer efficacy by acting as an agonist at M₁ and M₄ muscarinic acetylcholine receptors in the brain, and trospium chloride reduces the peripheral cholinergic adverse events associated with xanomeline. Xanomeline/trospium chloride received its first approval on 26 September 2024 in the USA for the treatment of schizophrenia in adults. This article summarizes the milestones in the development of xanomeline/trospium chloride leading to this first approval for schizophrenia.

查看原文本刊更多论文

Xanomeline/Trospium Chloride：首次批准。

Xanomeline/trospium chloride （COBENFY™），前身为KarXT，是一种一流的口服固定剂量毒蕈碱激动剂/拮抗剂组合，正在开发用于精神分裂症和阿尔茨海默病精神病。黄嘌呤被认为是通过作为脑内M1和M4毒蕈碱乙酰胆碱受体的激动剂而发挥功效，而trospium chloride减少了与黄嘌呤相关的外周胆碱能不良事件。Xanomeline/trospium chloride于2024年9月26日在美国首次获得批准，用于治疗成人精神分裂症。本文总结了xanomeline/trospium chloride首次获批用于治疗精神分裂症的发展历程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs 医学-毒理学

CiteScore

22.70

自引率

0.90%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Drugs is a journal that aims to enhance pharmacotherapy by publishing review and original research articles on key aspects of clinical pharmacology and therapeutics. The journal includes: Leading/current opinion articles providing an overview of contentious or emerging issues. Definitive reviews of drugs and drug classes, and their place in disease management. Therapy in Practice articles including recommendations for specific clinical situations. High-quality, well designed, original clinical research. Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. AdisInsight Reports summarising development at first global approval. Moreover, the journal offers additional digital features such as animated abstracts, video abstracts, instructional videos, and podcasts to increase visibility and educational value. Plain language summaries accompany articles to assist readers with some knowledge of the field in understanding important medical advances.